Design Challenges for HIV-1 Vaccines Based on Humoral Immunity.

Structure-Based Reverse Vaccinology Failed in the Case of HIV Because it Disregarded Accepted Immunological Theory. Int J Mol Sci (2016) 0.75

HIV vaccine development and broadly neutralizing antibodies. Evol Med Public Health (2015) 0.75

Antibody neutralization and escape by HIV-1. Nature (2003) 21.48

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54

Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med (2012) 12.98

The antigenic structure of the HIV gp120 envelope glycoprotein. Nature (1998) 12.44

Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature (2006) 6.78

Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull (2001) 4.41

Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature (2011) 3.80

Rational HIV immunogen design to target specific germline B cell receptors. Science (2013) 3.55

Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), Is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol (2002) 3.47

Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell (2013) 3.04

HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J Immunol (1996) 2.58

Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS (2009) 2.53

Rational modifications of HIV-1 envelope glycoproteins for immunogen design. Curr Pharm Des (2007) 2.35

HIV evolutionary dynamics within and among hosts. AIDS Rev (2006) 2.32

Clonal selection in the germinal centre by regulated proliferation and hypermutation. Nature (2014) 2.16

Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site. PLoS Pathog (2009) 2.07

Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat Med (2014) 2.06

Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. Sci Transl Med (2014) 1.60

Recombination in HIV: an important viral evolutionary strategy. Emerg Infect Dis (1997) 1.59

Ending AIDS--is an HIV vaccine necessary? N Engl J Med (2014) 1.27

Within-host and between-host evolutionary rates across the HIV-1 genome. Retrovirology (2013) 1.21

Induction of CD8+ regulatory T cells protects macaques against SIV challenge. Cell Rep (2012) 0.99